Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
Rhea-AI Summary
Intelligent Bio Solutions (Nasdaq: INBS) completed its initial clinical Cut-off Study for the Intelligent Fingerprinting Drug Screening System detecting codeine in 40 adults, with data analysis finished by end of March 2026.
The company began a multi-site Method Comparison & Usability Study (expected complete end of June 2026) and will run an Interference Study (expected complete end of July 2026) to support an FDA 510(k) submission comparing results to an FDA-cleared predicate and LC-MS/MS confirmation.
Positive
- Cut-off study completed on schedule with data analysis by end of March 2026
- Method Comparison & Usability multi-site study initiated; expected completion by end of June 2026
- Interference Study launched in parallel; anticipated completion by end of July 2026
Negative
- Analyte scope limited to codeine in the initial cut-off study
- Clinical sample size was 40 adults, a limited cohort for broad generalization
- 510(k) submission pending; clearance and commercial launch remain subject to regulatory outcome
News Market Reaction – INBS
On the day this news was published, INBS declined 11.86%, reflecting a significant negative market reaction. Argus tracked a peak move of +29.4% during that session. Argus tracked a trough of -35.3% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $840K from the company's valuation, bringing the market cap to $6.24M at that time. Trading volume was exceptionally heavy at 8.3x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INBS was down 6.73% while momentum peers PAVM and NXL showed declines of 7.23% and 9.73% without news. Scanner data flags no peers moving in the same direction as INBS, pointing to a stock-specific reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Patent grant | Positive | +1.5% | Eighth European patent strengthening fingerprint drug screening IP portfolio. |
| Feb 25 | Manufacturing scale-up | Positive | -4.3% | First shipment of readers via Syrma Johari, boosting capacity and margins. |
| Feb 24 | Commercial partnership | Positive | -2.6% | Partnership with Bouygues UK to deploy fingerprint drug screening on 13 sites. |
| Feb 12 | Earnings report | Positive | -6.7% | Record Q2 revenue growth, higher margins, and $10M private placement. |
| Feb 05 | Earnings pre-announcement | Positive | -9.1% | Guided to ~48% YoY Q2 revenue growth and ~$2.01M H1 revenue. |
Recent positive operational and growth updates have often been followed by negative next-day price moves.
Over the past months, INBS reported strong growth, new partnerships, and IP expansion. Earnings on Feb 12, 2026 highlighted revenue of $896,774 (up 48% YoY) and H1 revenue of $2.01M with gross margin improving to 49%, yet the stock fell after that and other upbeat releases. The latest news continues advancement toward FDA 510(k) clearance, building on manufacturing scale-up and European deployment as the company prepares for U.S. entry.
Regulatory & Risk Context
An effective Form S-3 resale registration covers 6,896,550 shares. The company received $10.0 million gross from a prior private placement and will not receive proceeds from registered resales, but could receive up to $18.87 million if all underlying warrants are exercised for cash. The filing notes potential stock pressure from the large resale overhang and ongoing Nasdaq listing risks.
Market Pulse Summary
The stock dropped -11.9% in the session following this news. A negative reaction despite clinical progress fits a pattern where prior positive updates, including revenue growth and partnerships, were followed by declines of up to high single digits. The company has an effective resale registration for 6,896,550 shares and disclosed going-concern risks in recent filings, which could amplify concerns. Even as the 510(k) program advances with defined milestones through July 2026, dilution and balance-sheet worries may have weighed on sentiment.
Key Terms
510(k) regulatory
predicate device regulatory
liquid chromatography-tandem mass spectrometry medical
LC-MS/MS medical
fluorescence reader technical
interference study medical
multi-site technical
AI-generated analysis. Not financial advice.
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch
Company advances second phase of clinical program for 510(k) submission with method comparison, usability, and interference testing
NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its initial clinical Cut-off Study supporting the Company's FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine.
The clinical Cut-off Study evaluated codeine detection cut-off levels in 40 adults, with full data analysis completed as planned by the end of March 2026. The study used the Intelligent Fingerprinting Drug Screening Cartridge with the DSR-Plus fluorescence reader, compared results with an FDA-cleared predicate device, and confirmed findings through liquid chromatography-tandem mass spectrometry (“LC-MS/MS”) analysis.
INBS has now initiated the second phase of its clinical study program. This includes a multi-site Method Comparison and Usability Study. This study is designed to validate the system’s accuracy, usability, and workplace performance when operated by intended end users at several clinical sites. The Company expects to complete the Method Comparison and Usability Study by the end of June 2026. In parallel with the Method Comparison and Usability Study, the Company will be commencing an Interference Study, which will test the device in the presence of potentially interfering substances found in real-world settings. Completion of the Interference Study is anticipated by the end of July 2026.
"The U.S. drug screening market is a significant commercial opportunity for Intelligent Bio Solutions," said Harry Simeonidis, President and CEO at INBS, "The on-schedule completion of our Cut-off Study validates our clinical approach and keeps us firmly on track toward our FDA 510(k) submission and planned commercial launch."
The U.S. drug screening market represents a multi-billion-dollar annual opportunity. Major segments include workplace testing, criminal justice, pain management, and substance abuse treatment. The Company’s non-invasive fingerprint technology offers several advantages over traditional urine, oral fluid, and blood testing methods. Benefits include a detection window designed to identify current impairment rather than past use, rapid results, and the ability to conduct screening at any time and location.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: https://ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
